---

Amphetamine / MDMA Toxicity: A Complete Toxicological Analysis

---

(a) Mechanism of Toxicity of Sympathomimetic Amines - Receptor Pharmacology

Core Molecular Mechanism

Step 1 - Plasma Membrane Transporter Reversal (DAT / NET / SERT)

• DAT (Dopamine Transporter) - primary target for amphetamine/methamphetamine
• NET (Norepinephrine Transporter) - responsible for sympathomimetic effects
• SERT (Serotonin Transporter) - especially targeted by MDMA

Step 2 - VMAT2 Disruption

• Deplete synaptic vesicles of monoamine content
• Raise cytoplasmic free monoamine concentrations dramatically
• Provide substrate for reverse DAT/NET/SERT transport into the synapse

• Katzung's Basic and Clinical Pharmacology, 16th Edition
• Stahl's Essential Psychopharmacology

Step 3 - MAO Inhibition

MDMA: The "Serotonergic Amphetamine"

• Tintinalli's Emergency Medicine, Chapter on Hallucinogenic Amphetamines
• Katzung's Basic and Clinical Pharmacology, 16th Edition

The Sympathomimetic Toxidrome - Physiological Consequences

• ROSEN's Emergency Medicine, Clinical Features of Sympathomimetic Toxicity
• Washington Manual of Medical Therapeutics

---

(b) Serotonin Syndrome vs. Neuroleptic Malignant Syndrome - Differential Diagnosis

Comparative Table

• Localization in Clinical Neurology, 8th Edition, Table 17-3
• Tintinalli's Emergency Medicine, Table 178-10

Hunter Criteria for Serotonin Syndrome

1. Spontaneous clonus
2. Inducible clonus WITH agitation or diaphoresis
3. Ocular clonus WITH agitation or diaphoresis
4. Tremor AND hyperreflexia
5. Hypertonia AND temperature >38°C AND ocular/inducible clonus

Why This Case Favors SS Over NMS

• Ingested MDMA (serotonergic agent) - the precipitant for SS, not a dopamine blocker
• Rapid onset (acute ingestion)
• No history of neuroleptic use (required for NMS)
• Hyperthermia + altered sensorium + tachycardia

Anticholinergic Toxidrome - Third Differential

Treatment Implications

• Tintinalli's Emergency Medicine, treatment sections 178 and 180

---

(c) Forensic Workup: Biological Sampling, Hair Drug Testing & NDPS Act 1985

Biological Sampling Strategy - Tiered Approach

Tier 1 - Acute Clinical/Medicolegal Samples (Collect IMMEDIATELY)

Detection Windows - Acute Specimens

• Urine: amphetamines detectable 2-4 days post-ingestion (immunoassay cutoff 1000 ng/mL in SAMHSA-regulated testing, 500 ng/mL in many clinical labs)
• Blood: short detection window (8-24 hours); valuable for quantitation in acute cases
• MDMA is cross-reactive on standard urine amphetamine immunoassays (monoclonal antibodies detect it) but GC-MS or LC-MS/MS confirmation is mandatory for legal purposes

Tier 2 - Confirmatory/Legal Testing

1. Immunoassay screen (EMIT, CLIA, ELISA) - rapid, presumptive
2. GC-MS or LC-MS/MS confirmation - definitive, legally defensible; different analytical principle from the screen

• Henry's Clinical Diagnosis and Management by Laboratory Methods

Tier 3 - Chain of Custody Protocol

1. Observed collection (documented witness)
2. Tamper-evident seals on each container, initialed by collector and witness
3. Specimen temperature recording (must be 90-100°F / 32-38°C for urine - outside this range suggests substitution)
4. Requisition form with time, date, collector ID, patient ID
5. Specimen validity testing (urine): creatinine, specific gravity, pH, nitrites, oxidizing agents
6. Continuous documentation from collection to analysis to court - every transfer signed

• Henry's Clinical Diagnosis and Management by Laboratory Methods, Chain of Custody section

Hair Drug Testing

Pharmacokinetics of Hair Incorporation

• Drugs in blood are incorporated into the hair follicle during keratinization
• Hair grows at approximately 1 cm per month
• The standard forensic sample is 3 cm from the root = approximately 90 days (3 months) of history
• Segment analysis (1 cm per segment) allows month-by-month timeline of drug use

Hair Collection Protocol

1. Cut close to scalp from vertex posterior region (least affected by cosmetic treatment)
2. Minimum 100 mg of hair (approximately 50-70 strands)
3. Bundle with tape, root end marked
4. Store in foil - protect from light and humidity
5. Document collection site, color, length

Analytical Process for Hair

1. Decontamination wash (methanol/water - removes external contamination from passive exposure)
2. Enzymatic digestion or solvent extraction to release incorporated drug
3. Immunoassay screen followed by LC-MS/MS confirmation
4. Report as pg/mg of hair (picograms per milligram)

• Pattern of use (occasional vs. chronic)
• Timeline of first use and cessation
• Defense against acute spiking (hair cannot be acutely manipulated)

Limitations of Hair Testing

• Cannot distinguish single acute dose (this case) from chronic use without segment analysis
• Melanin binding - drugs incorporate more into darker hair (potential racial bias)
• External contamination (hair dye, sweat) can cause false positives
• Washout procedures must be standardized
• Bleaching/perming can reduce drug concentrations by 40-60%

Legal Framework: NDPS Act 1985

Scheduled Status of Amphetamine and MDMA

• Amphetamine (+)-2-amino-1-phenylpropane - explicitly listed in the NDPS Act Schedule
• MDMA (3,4-methylenedioxy-methamphetamine) - listed as a psychotropic substance
• Small quantity (amphetamine): triggers reduced punishment provisions
• Commercial quantity (amphetamine): 1,500 grams - triggers minimum 10 years rigorous imprisonment with fine; can extend to death penalty for repeat offences at commercial quantities

Key Sections Relevant to Forensic Workup

Narcotics Control Bureau (NCB)

Medicolegal Duties of the Treating Physician

1. Preserve all biological specimens with documented chain of custody - do not discard without forensic documentation
2. Mandatory reporting: Under Sec. 57, officers (including medical officers) must report seizures/apprehensions to the immediate superior
3. Detailed MLC (Medico-Legal Certificate) documenting:
   • Time of admission, clinical findings, vital signs
   • Toxiscreen results (screen + confirmation)
   • Treatment given
   • Patient's statement (if capable of giving one)
4. Do not reveal results to parties other than law enforcement/court without proper authorization (doctor-patient confidentiality vs. public interest in NDPS cases - courts have held public safety overrides)
5. Samples sealed, signed, and sent to FSL (Forensic Science Laboratory) under the state government

Evidence Chain Under NDPS Act

• Sec. 52A requires that sampling of seized drugs be done in the presence of a magistrate - biological specimens from patients are handled analogously
• Any break in chain of custody can lead to acquittal on technical grounds
• The 2014 amendment and subsequent Supreme Court rulings (notably Mohan Lal v. State of Punjab, 2018) held that the same officer cannot be both the informant and the investigating officer, reinforcing need for independent forensic documentation

---

Summary Diagram

MDMA/Amphetamine Ingestion
        |
        ↓
VMAT2 disruption → vesicle depletion
DAT/NET/SERT reversal → massive monoamine flood
        |
   ┌────┴────┐
   ↓         ↓
Catecholamines    Serotonin
(↑DA, NE)          (↑5-HT)
   |                  |
Sympathomimetic    Serotonin syndrome
Toxidrome:         risk:
- Tachycardia      - Clonus
- Hypertension     - Hyperthermia
- Mydriasis        - Myoclonus
- Agitation        - Hyperreflexia
   |                  |
   └────┬────┘
        ↓
Confirm SS vs NMS:
→ Check for clonus (SS) vs lead-pipe rigidity (NMS)
→ CPK normal (SS) vs elevated (NMS)
→ History: serotonergic drug (SS) vs dopamine blocker (NMS)

• Katzung's Basic and Clinical Pharmacology, 16th Edition - AMPHETAMINES section
• Tintinalli's Emergency Medicine, A Comprehensive Study - Ch. 178 (Serotonin Syndrome), Ch. 178 (Comparison Table)
• Stahl's Essential Psychopharmacology - VMAT2 mechanism
• ROSEN's Emergency Medicine - Sympathomimetic Toxidrome
• Localization in Clinical Neurology, 8th Edition - NMS Differential Table 17-3
• Henry's Clinical Diagnosis - Chain of Custody, Forensic Testing
• Washington Manual of Medical Therapeutics - Amphetamine Pathophysiology
• NDPS Act, 1985 (Act No. 61 of 1985) - Sections 27, 37, 42, 43, 50, 52A, 57